Tackling HLA Deficiencies Head on with Oncolytic Viruses
Open Access
- 10 February 2021
- Vol. 13 (4), 719
- https://doi.org/10.3390/cancers13040719
Abstract
Dysregulation of HLA (human leukocyte antigen) function is increasingly recognized as a common escape mechanism for cancers subject to the pressures exerted by immunosurveillance or immunotherapeutic interventions. Oncolytic viruses have the potential to counter this resistance by upregulating HLA expression or encouraging an HLA-independent immunological responses. However, to achieve the best therapeutic outcomes, a prospective understanding of the HLA phenotype of cancer patients is required to match them to the characteristics of different oncolytic strategies. Here, we consider the spectrum of immune competence observed in clinical disease and discuss how it can be best addressed using this novel and powerful treatment approach.Funding Information
- Cancer Research UK (C552/A29106)
This publication has 107 references indexed in Scilit:
- IRF1 and NF-kB Restore MHC Class I-Restricted Tumor Antigen Processing and Presentation to Cytotoxic T Cells in Aggressive NeuroblastomaPLOS ONE, 2012
- Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of CancerMolecular Therapy, 2011
- Identification of Genetically Modified Maraba Virus as an Oncolytic RhabdovirusMolecular Therapy, 2010
- Impact of tumor microenvironment on oncolytic viral therapyCytokine & Growth Factor Reviews, 2010
- Immunogenic and tolerogenic cell deathNature Reviews Immunology, 2009
- ER stress affects processing of MHC class I-associated peptidesBMC Immunology, 2009
- Modulators of arginine metabolism support cancer immunosurveillanceBMC Immunology, 2009
- STING is an endoplasmic reticulum adaptor that facilitates innate immune signallingNature, 2008
- Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon CancerPLOS ONE, 2008
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002